Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01332604 · ClinicalTrials.gov registry record · Phase 1
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01332604 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 41 participants.
The verdict
NCT01332604, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase Ib, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0980 administered in combination with capecitabine and with mFOLFOX6 chemotherapy with bevacizumab added on at Cycle 5 in patients with advanced or metastatic solid tumors.
Interventions
- DRUG bevacizumab
- DRUG capecitabine
- DRUG mFOLFOX6
- DRUG GDC-0980
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01332604
The ClinicalTrials.gov registry entry for NCT01332604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bevacizumab is the first listed.
NCT01332604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01332604 about?
NCT01332604 is a clinical study titled "GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors". This is an open-label, multicenter, Phase Ib, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0980 administered in combination with capecitabine and with mFOLFOX6 chemotherapy with bevacizumab added on at Cycle 5 in patients with advanced or metast...
What is the current status of trial NCT01332604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2011-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01332604?
The interventions under investigation include: bevacizumab (DRUG), capecitabine (DRUG), mFOLFOX6 (DRUG), GDC-0980 (DRUG).
Who is sponsoring clinical trial NCT01332604?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.